Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 7/20 | 0.37 |
| ▸ | CDK2 | P24941 | 7/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 7/20 | 0.37 |
| ▸ | AURKA | O14965 | 6/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 8/20 | 0.34 |
| ▸ | EP300 | Q09472 | 6/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2920173 | 0.82 | CCNA2 (0.39) | CCNA2CDK2CCNA1AURKANOTUM | |
| SCHEMBL5720799 | 0.76 | CCNA2 (0.47) | CCNA2CDK2CCNA1AURKANOTUM | |
| SCHEMBL2915617 | 0.73 | AURKA (0.44) | CCNA2CDK2CCNA1AURKACREBBP | |
| SCHEMBL2916804 | 0.72 | MTOR (0.35) | CCNA2CDK2CCNA1AURKAMAPK1 | |
| SCHEMBL5720830 | 0.71 | BTK (0.47) | CCNA2CDK2CCNA1AURKACREBBP | |
| SCHEMBL2919942 | 0.71 | CCNA2 (0.41) | CCNA2CDK2CCNA1CREBBPEP300 | |
| SCHEMBL2913543 | 0.70 | CCNA2 (0.39) | CCNA2CDK2CCNA1AURKACREBBP | |
| SCHEMBL5720882 | 0.69 | AURKA (0.51) | CCNA2CDK2CCNA1AURKACREBBP | |
| SCHEMBL2924399 | 0.69 | KDM4E (0.40) | MAPK1MAPT | |
| SCHEMBL2918879 | 0.68 | MAPT (0.49) | CCNA2CDK2CCNA1AURKAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541354-B2 | Bicyclo-pyrazoles | PFIZER ITALIA S.R.L. (IT) | 2009-06-02 | — | — | US | disclosed |
| US-20030171357-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171357-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K20, MAP3K19, MAP3K1 | CCNA2 848/4885CDK2 43/4885CCNA1 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.